First Patient Dosed in SANTANA-225 Ph 1/2 Trial of 225Ac-SSO110 in Patients with ES-SCLC or MCC
“RLTs are redefining precision oncology by enabling targeted delivery of radiation directly to tumor cells while minimizing exposure to healthy tissue,” said Germo Gericke, MD, Chief Medical Officer of Ariceum Therapeutics. “225Ac-SSO110 is the first SSTR2 antagonist RLT in clinical development, designed to deliver higher doses of alpha radiation directly to patients’ tumors while maintaining a favorable safety profile for individuals with neuroendocrine cancers, including ES-SCLC and MCC. Dosing the first patient in the SANTANA-225 trial is a significant step for our lead program and an important milestone towards addressing urgent patient needs in these aggressive cancers. We expect to report initial safety data from the SANTANA-225 trial in 2026, which may support expansion into additional neuroendocrine tumor indications and further validate the differentiated mechanism of action of 225Ac-SSO110.”
Share:
More News
“The designation reinforces the significant unmet need for effective treatment options for patients with advanced breast cancer,” said Charles Baum, M.D., Ph.D., Chief Executive Officer of Terremoto Biosciences. “We are committed to advancing highly selective therapies designed to expand treatment options for patients with difficult to treat cancers.”
“Up to five U.S. clinical sites are planned for THIO-101 Parts C and D this year, and we expect to activate a second U.S. site in the coming weeks,” said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA. “To date, data has shown overall survival (OS) beyond two
Dr. Jason Zhu, Executive Director and Chief Executive Officer of Henlius, said: “The positive CHMP opinion for the sqNSCLC indication marks another important milestone in serplulimab’s regulatory journey in Europe and brings the product one step closer to achieving comprehensive coverage of first-line lung cancer treatment indications in the EU.